In vivo pharmacokinetics, therapeutic efficacy and immune response of bacteriophage vB_AbaSt_W16 against carbapenem-resistant Acinetobacter baumannii

Le résumé fourni par la source

Abstract Background The increasing prevalence of carbapenem-resistant Acinetobacter baumannii (CRAB) infections necessitates alternative therapeutic strategies. Bacteriophage therapy has emerged as a promising approach, yet its clinical implementation is hindered by limited pharmacokinetic (PK) and pharmacodynamic (PD) data. Methods The PK and PD properties of Acinetobacter phage vB_AbaSt_W16 were evaluated in a murine model. Systemic distribution, clearance kinetics and efficacy were assessed following oral (PO) and intraperitoneal (IP) administration. Conventional PK/PD analysis and real-time fluorescence imaging were used to examine in vivo phage dynamics. Results After administration, vB_AbaSt_W16 rapidly disseminated systemically within 1 h, reaching peak concentrations at 8 h. Most tissues cleared the phage within 72 h, though residual amounts persisted in the spleen for up to 92 h. In a murine infection model, vB_AbaSt_W16 demonstrated potent antibacterial activity, reducing CRAB bacterial loads by 4–7 log₁₀ cfu/mL within 24 h. Compared with PO administration, IP administration resulted in higher systemic bioavailability and bacterial clearance. Fluorescence imaging enabled non-invasive, real-time monitoring of phage distribution, demonstrating its utility as a PK assessment tool. Notably, phage treatment did not trigger significant pro-inflammatory cytokine release (TNF-α, IL-6) in healthy mice and effectively reduced CRAB-induced inflammation. Conclusions These findings highlight the therapeutic potential of vB_AbaSt_W16 and provide critical insights into its PK behaviour. The results support further clinical development of this phage for CRAB infections.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.